European medical agency : “Lynparza”. (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/human_med_001831.jsp&mid=WC0b01ac058001d124)(2017年5月閲覧)
Kim G, Ison G, McKee AE, et al : FDA Approval Summary : Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy. Clin Cancer Res 21 : 4257-4261, 2015
Ledermann J, Harter P, Gourley C, et al : Olaparib maintenance therapy in patients with plarinum-sensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in randomized phase 2 trial. Lancet Oncology 15 : 852-861, 2014